Recent 8-K filings for NEUP

• January 8, 2026, 6:59 PM ET leadership materiality 0.60 neutral item 1.01item 1.02item 9.01

  CEO Spyridon Papapetropoulos transitions to interim CEO under consulting agreement

  Employment terminated Dec 31, 2025; Papapetropoulos remains on Board of Directors.

• December 18, 2025, 6:59 PM ET regulatory materiality 0.75 positive item 3.01 ◈ Listing & Compliance Notices

  Neuphoria Therapeutics regains Nasdaq compliance after holding 2025 annual meeting

  Received Nasdaq deficiency notice on July 18, 2025 for failing to hold annual meeting within 12 months of FY end (Rule 5620(a)).

• October 27, 2025, 7:59 PM ET other material materiality 0.70 neutral item 1.01item 3.03item 5.03item 8.01item 9.01 ◈ Equity Issuances◈ Governance Changes

  Neuphoria adopts poison pill after investor accumulates >20%; launches strategic review

  Rights plan triggered if any entity acquires 15%+ beneficial ownership without board approval.

• October 20, 2025, 7:59 PM ET other material materiality 0.90 negative item 8.01item 9.01

  Neuphoria Phase 3 trial of BNC210 for social anxiety disorder fails primary endpoint; SAD program discontinued

  AFFIRM-1 Phase 3 trial did not meet primary endpoint of change in SUDS scores during speech challenge; secondary endpoints also not significant.

• May 20, 2025, 7:59 PM ET other material materiality 0.70 neutral item 2.02item 9.01

  Neuphoria Q1 update: BNC-210 Phase 3 topline due Q3 2025; cash runway into Q3 2026

  Cash runway extends into Q3 2026; no near-term financing risk stated.

• December 23, 2024, 6:59 PM ET other material materiality 0.75 neutral item 1.01item 3.01item 3.02item 3.03item 5.03item 8.01item 5.01item 5.02item 5.05item 9.01 ◈ Governance Changes ×3◈ M&A Transactions

  Neuphoria completes redomiciliation from Australia to Delaware; shares to trade under NEUP

  Effective Dec 23, 2024, Bionomics Ltd. became a wholly-owned subsidiary of Neuphoria; NEUP shares to trade on Nasdaq from Dec 24.

• December 16, 2024, 6:59 PM ET other material materiality 0.60 neutral item 8.01item 9.01

  Court approves Bionomics' re-domiciliation; Neuphoria to list Dec 24 under NEUP

  Supreme Court of NSW approved Scheme of Arrangement on Dec 16, 2024; scheme became legally effective after lodgment with ASIC.

• November 8, 2024, 6:59 PM ET M&A materiality 0.60 neutral item 8.01item 9.01

  Bionomics announces amended exchange ratio for re-domicile merger; court approves Dec 12 meeting

  Amended exchange ratio: 1 Neuphoria share per 2,160 Bionomics ordinary shares; 1 per 12 ADSs.

• October 2, 2024, 7:59 PM ET other material materiality 0.70 neutral item 1.01item 9.01

  Bionomics to re-domicile from Australia to US via scheme of arrangement with Neuphoria

  Holders receive 1 Neuphoria share per 1,440 ordinary shares or per 8 ADSs; estimated post-domicile Nasdaq price ~$3.50.

• July 16, 2024, 7:59 PM ET regulatory materiality 0.70 negative item 3.01

  Bionomics receives Nasdaq bid price deficiency notice; has until Jan 7, 2025 to regain compliance

  Nasdaq notified Bionomics on July 11, 2024 that its ADS bid price closed below $1.00 for 30 consecutive business days.

Executive changes

Materiality & sentiment trend

Max materiality 0.90 · Median 0.60 · Most common event other_material

2 positive 2 negative 14 neutral

source · NEUP on sec.gov